An observational study in Pulmonary Hypertension, sponsored by Royal United Hospitals Bath NHS Foundation Trust. Recruiting at 5 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-18.
Sponsored by Royal United Hospitals Bath NHS Foundation Trust · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 117 studies in Hypertension, Pulmonary with a site in United Kingdom — 22 open to participants now, 27 under way, 3 of them phase 3. Hypertension, Pulmonary · United Kingdom.
Among the 117 studies in Hypertension, Pulmonary with a site in United Kingdom, this one has the largest planned enrollment of the 33 observational ones that give a count, is one of 5 that started in 2024, is one of 33 observational ones, reaches primary completion later than 9 of the 26 other live ones, and was the 102nd registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.
Browse Hypertension, Pulmonary studies →22 of the 117 studies in Hypertension, Pulmonary with a site in United Kingdom are open now. Recruiting first, the newest first:
University of Glasgow · Sites in United Kingdom
Ages 18+
Regeneron Pharmaceuticals · Sites in United Kingdom, United States, Australia and 7 more countries
Ages 18+
Liquidia Technologies, Inc. · Sites in United Kingdom, United States, Australia and 9 more countries
Ages 18–80
Golden Jubilee National Hospital · Sites in United Kingdom
Ages 18+
Insmed Incorporated · Sites in United Kingdom, United States, Argentina and 27 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
117 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 30 · Phase 3 32 · Phase 4 2
First in 2002; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,500 is above the median of 110 across 380 observational studies indexed under Hypertension, Pulmonary.
Median enrollment 86 across the 83 interventional studies, 200 across the 33 observational. Of the 77 that completed or were terminated, 43 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
63 of 117 have an industry lead sponsor. The 10 most frequent:
Royal United Hospitals Bath NHS Foundation Trust is the lead sponsor of 19 studies on the registry; 7 are open to participants now.
Royal United Hospitals Bath NHS Foundation Trust has 4 studies filed under Hypertension, Pulmonary — fewer than ten, so there is no comparison to draw.
9 of the studies in Hypertension, Pulmonary with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT07311135Golden Jubilee National HospitalAccuracy of Smartwatches in Measuring Oxygen Levels in Patients With Pulmonary Hypertension: A Pilot Study | 2026-12 |
| NCT06386185Royal United Hospitals Bath NHS Foundation TrustDeveloping the Probability Algorithm for Pulmonary Hypertension Echocardiography | 2026-12-01 |
| NCT07102823Medical University of GrazClinical Registry for the Characterization of the 'Pulmonary Vascular Phenotype' in Patients With Chronic Obstructive Pulmonary Disease | 2026-12-30 |
| NCT07754981University of SheffieldSelf-Help Booklets for Sleep in Adults With Pulmonary Hypertension | 2027-03 |
Add all 9 to your calendar (.ics) → With an account.
Among the 117 studies in Hypertension, Pulmonary with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to assess the efficacy that the addition of novel markers cardiac function, particularly of right ventricular (RV) function in echocardiography, and ECG have in detecting pulmonary hypertension.
The main questions it aims to answer are:
Can novel markers in ECG and echocardiography suggest the presence of PH? Can existing screening guidelines be improved with the addition of these markers?
Pulmonary Hypertension (PH) is a condition caused by high blood pressure in the blood vessels that carry blood to the lungs. It can cause severe breathlessness and failure of the right side of the heart. Sadly it is often fatal.
PH can be caused by a number of different conditions and life expectancy varies with the underlying cause, ranging from months to years. For some subtypes of PH, effective treatments exist which can significantly improve life expectancy and quality of life. Accurate tools for the assessment of PH are therefore essential, so that we can better understand and predict life expectancy and so that life-saving medications can be started earlier.
Once doctors suspect that somebody has PH, they refer them to a specialist PH centre for assessment and a procedure called right heart catheterisation (RHC), which will confirm the diagnosis. However, evidence for the suspicion of PH is frequently overlooked, leading to an average delay to diagnosis from onset of symptoms of two years. This late presentation negatively impacts survival for these patients and prevents them promptly starting the effective treatments which are available.
An electrocardiogram (ECG) is a recording of the heart's electrical signals, printed in waveforms. It is a painless, low-cost, and readily-available test used in PH assessment.
Echocardiography (echo) is a quick, safe and well-tolerated test often requested to investigate breathless patients and can provide useful information about the suspicion of PH. Echo has however been shown to lack accuracy in milder forms of the disease. It has been hypothesised that subtle markers of right ventricular function by echo, such as free wall strain (RVFWS) begin to deteriorate before the more established findings.
A large, cross-population study of ECG features and echo markers such as RVFWS both in isolation and in combination, in patients referred for PH assessment may help identify these markers, and improve detection of the disease.
Patients aged 18+ referred for first time assessment of PH, who have undergone ECG, TTE, and RHC as part of their routine investigation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients referred for initial PH investigations, who underwent ECG and echo screening prior to RHC.
Diagnostic Test: Electrocardiogram · Diagnostic Test: Transthoracic echocardiogram · Diagnostic Test: Right heart catheter
Non-invasive multi-vector voltage/time graph visualising the electrical conduction of the heart
Also known as: ECG
Non-invasive 2 \& 3 dimensional imaging of the heart using ultrasound
Also known as: Echo, TTE
Minimally invasive cardiac chamber pressure measurement using balloon catheterisation
Also known as: RHC
Distinguish between patients with and without pulmonary hypertension
Assessment of novel echo markers of cardiac function in improving the current assessment framework's ability to correctly identify or exclude the presence of pulmonary hypertension based on a mean pulmonary artery pressure greater than 20mmHg as measured by right heart catheter. There is no reporting scale, rather markers will be used to assess a binary yes/no with regards to the presence of pulmonary hypertension
Time frame: 2 years
Distinguish between patients with pre-capillary hypertension and post-capillary hypertension
Assessment of novel echo markers of cardiac function in determining the subtype of pulmonary hypertension (i.e. pulmonary hypertension secondary to left heart disease, or pulmonary hypertension emanating from pulmonary abnormality) based on a mean pulmonary artery pressure greater than 20mmHg, pulmonary vascular resistance, or pulmonary capillary wedge pressure as measured by right heart catheter. There is no reporting scale, rather markers will be used to assess a binary yes/no with regards to the presence of pulmonary hypertension
Time frame: 2 years
Assess the impact of the severity of pulmonary hypertension
Existing research has demonstrated that current assessment guidelines are less accurate in milder forms of pulmonary hypertension. We aim to assess any improvements to the overall efficacy that novel markers of cardiac function may have, particularly in those with low echocardiographic probability as determined by European Society of Cardiology echocardiographic guidelines for the assessment of pulmonary hypertension. There is no reporting scale, rather markers will be used to assess a binary yes/no with regards to the presence of pulmonary hypertension
Time frame: 2 years
Assess the impact of additional electrocardiogram markers on existing pulmonary hypertension probability stratification
Assessment of novel electrocardiogram markers in improving pulmonary hypertension assessment guidelines, particularly in those with low echocardiographic probability as determined by European Society of Cardiology echocardiographic guidelines for the assessment of pulmonary hypertension. There is no reporting scale, rather markers will be used to assess a binary yes/no with regards to the presence of pulmonary hypertension
Time frame: 2 years
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Royal United Hospitals Bath NHS Foundation Trust